First Images on a Next-Generation Extended–Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT

Key Points

• The research aims to assess the effectiveness of next-generation imaging technology for detecting biochemical recurrence of prostate cancer.
• Performed 18F-DCFPyL PET/CT imaging after injection of 341 MBq of the radiotracer.
• Focused on a patient with Gleason grade group 3 prostate cancer and biochemical recurrence indicators.
• Detected biochemical recurrence with a PSA level of 8.0 ng/mL, suggesting effective imaging capabilities.
• Imaging conducted 12 years post-radical prostatectomy, highlighting the durability of detection.